CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson
This article was originally published in The Pink Sheet Daily
Executive Summary
A2A-adenosine agonist could see FDA action by mid-March 2008.
You may also be interested in...
FDA Clears Astellas’ Lexiscan For Market
Bigger sales force backs soon-to-launch imaging agent.
FDA Clears Astellas’ Lexiscan For Market
Bigger sales force backs soon-to-launch imaging agent.
Acusphere Again Delays Imagify NDA, Cites Lengthy Manufacturing Ramp-Up
Firm now targets an early 2008 submission for the cardiac perfusion imaging agent.